Indian pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine.
The first dosage of its plasmid DNA vaccine ZyCoV-D was administered to a human test subject on Wednesday, the company said in a statement.
The vaccine elicited a strong immune response during trials in animal species including mice, rats, guinea pigs and rabbits.
No safety concerns were observed.
“In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic,’’ Zydus said.
The company said the DNA vaccine platform it had developed could be used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.
India, along with several other countries, has been fast-tracking and supporting the development of a Covid-19 vaccine as the numbers of infections and deaths swell.
Currently India ranks third after the United States and Brazil among countries worst hit by the pandemic, with 936,181 infections and a death toll of 24,209 officially confirmed, according to the latest Health Ministry data.
Several regions in India have announced fresh lockdowns, including IT hub Bangalore, as cases continue to spiral.
Nearly 30,000 new cases and 582 deaths were reported on Tuesday.
Edited By: Halima Sheji/Sadiya Hamza (NAN)
- Tanker drivers start strike Monday as talks with LASG end in deadlock
- NCDC confirms 437 new COVID-19 case, total of infection hits 46,577
- Apapa will open to traffic in October — LASG
- Halep to decide on United States Open after Prague event
- Gov. Fayemi mourns ex-Ekiti lawmaker, Fakiyesi
- Vettel says Ferrari messed up with nonsensical strategy
- Ekiti Govt paying lip service to healthcare delivery, say striking doctors
- Resumption: Academy wants COVID-19 protocol funds released directly to schools
- Willian confirms exit from Chelsea after 7 years
- Anglican Bishop urges govts to save SMEs from collapse